- Filippo Belardelli - Istituto Superiore di Sanità, Italy
- Douglas Bettcher - World Health Organization, Switzerland
- Franco Cavalli1 - Oncology Institute of Southern Switzerland, Switzerland
- Gauden Galea - World Health Organization Regional Office for Europe, Denmark
- Gilbert Lenoir - Institut Gustave Roussy, France
- Jose M. Martin-Moreno - University of Valencia, Spain
- Florian Alexandru Nicula - Oncology Institute "Prof. Dr I. Chiricuta", Romania
- Jørgen H. Olsen - Danish Cancer Society Research Center, Denmark
- Julietta Patnick - Public Health England, United Kingdom
- Maja Primic-Žakelj - Institute of Oncology, Slovenia
- Pekka Puska2 - National Institute for Health and Welfare, Finland
- Flora E. van Leeuwen - Netherlands Cancer Institute, The Netherlands
- Otmar Wiestler3 - German Cancer Research Center (DKFZ), Germany
- Witold Zatonski - Maria Skoldowska-Curie Cancer Center and Institute of Oncology, Poland
1 F. Cavalli has been involved in an international Phase III trial (iELS6 Trial 19) from Roche.
2 In June 2014, after completion of work on the development of the ECAC, P. Puska began serving as chair of the International Advisory Board of MEDIETA Ltd, a commercial entity that manufactures mobile patient monitoring systems. He receives approximately 11,000 euros per year for this activity.
3 O. Wiestler has served as chair of the Scientific Advisory Boards for Siemens and Bayer.